\-\ Texto\\:\\ \ \(0\)\
\-\ multiple\\ erythematous\\ nodules\\,\\ some\\ with\\ superficial\\ ulceration\\,\\ and\\ plaques\\ distributed\\ over\\ hands\\,\\ wrists\\,\\ forearms\\,\\ bilateral\\ lower\\ extremities\\,\\ and\\ feet\\.\\ hyperpigmented\\ plaques\\ on\\ scalp\\.\ \(0\)\
\-\ heme\\/onc\\ administered\\ 6\\ cycles\\ of\\ chop\\ chemotherapy\\ with\\ clinical\\ remission\\ of\\ the\\ nodules\\.\\ biopsy\\ was\\ performed\\ at\\ three\\ previously\\ involved\\ sites\\,\\ which\\ revealed\\ an\\ atypical\\ t\\-cell\\ lymphoid\\ infiltrate\\ felt\\ to\\ represent\\ residual\\ t\\-cell\\ lymphoma\\.\\ total\\ skin\\ electron\\ beam\\ \\(tseb\\)\\ therapy\\ was\\ administered\\ for\\ 9\\ weeks\\.\\ the\\ patient\\ had\\ clinical\\ remission\\ of\\ all\\ active\\ lesions\\.\\ follow\\ up\\ was\\ scheduled\\ for\\ 3\\ months\\ after\\ completing\\ tseb\\.\ \(0\)\
\-\ plaques\\ and\\ nodules\\ with\\ superficial\\ ulceration\\ on\\ bilateral\\ lower\\ extremities\\.\ \(0\)\
\-\ cutaneous\\ t\\-cell\\ lymphoma\\ \\(case\\ 1\\,\\ 25th\\ annual\\ uniformed\\ services\\ dermatology\\ seminar\\,\\ san\\ antonio\\,\\ tx\\)\ \(0\)\
\-\ mycosis\\ fungoides\\(guttate\\ dermatosis\\)\\ \ \(0\)\
\-\ pityriasis\\ rosea\\ \ \(0\)\
\-\ eczema\ \(6\)\
\-\ neurodermatitis\ \(0\)\
\-\ pseudolymphoma\\ syndrome\ \(0\)\
\-\ diagnosed\\ with\\ mycosis\\ fungoides\\ in\\ april\\ 1997\\.\\ now\\ presenting\\ in\\ june\\ 1998\\ with\\ plaques\\ on\\ lower\\ extremities\\ and\\ face\\ recalcitrant\\ to\\ treatment\\ with\\ topical\\ nitrogen\\ mustard\\ and\\ corticosteroids\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ t\\-cell\\:\\ 0\\.11844152198122733\ \(0\)\
\-\ plaques\\:\\ 0\\.10971188864671144\ \(0\)\
\-\ tseb\\:\\ 0\\.10132779797662642\ \(0\)\
\-\ fungoides\\:\\ 0\\.08870007052067112\ \(0\)\
\-\ mycosis\\:\\ 0\\.08539338003271962\ \(0\)\
\-\ remission\\:\\ 0\\.06945896208881283\ \(0\)\
\-\ nodules\\:\\ 0\\.061077911472461235\ \(0\)\
\-\ ulceration\\:\\ 0\\.0604617283043343\ \(0\)\
\-\ extremities\\:\\ 0\\.05778770032656704\ \(0\)\
\-\ administered\\:\\ 0\\.05659423133167668\ \(0\)\
\-\ superficial\\:\\ 0\\.052494519332380904\ \(0\)\
\-\ dermatosis\\:\\ 0\\.05066389898831321\ \(0\)\
\-\ rosea\\:\\ 0\\.05066389898831321\ \(0\)\
\-\ neurodermatitis\\:\\ 0\\.05066389898831321\ \(0\)\
\-\ pseudolymphoma\\:\\ 0\\.05066389898831321\ \(0\)\
\-\ recalcitrant\\:\\ 0\\.05066389898831321\ \(0\)\
\-\ mustard\\:\\ 0\\.05066389898831321\ \(0\)\
\-\ guttate\\:\\ 0\\.04668029450233651\ \(0\)\
\-\ pityriasis\\:\\ 0\\.04668029450233651\ \(0\)\
\-\ heme\\/onc\\:\\ 0\\.04269669001635981\ \(0\)\
\-\ 25th\\:\\ 0\\.04269669001635981\ \(0\)\
\-\ chop\\:\\ 0\\.041414255813404584\ \(0\)\
\-\ electron\\:\\ 0\\.041414255813404584\ \(0\)\
\-\ nitrogen\\:\\ 0\\.041414255813404584\ \(0\)\
\-\ forearms\\:\\ 0\\.040366430774358864\ \(0\)\
\-\ completing\\:\\ 0\\.040366430774358864\ \(0\)\
\-\ eczema\\:\\ 0\\.040366430774358864\ \(0\)\
\-\ 1997\\.\\:\\ 0\\.040366430774358864\ \(0\)\
\-\ hyperpigmented\\:\\ 0\\.039480507327075774\ \(0\)\
\-\ antonio\\:\\ 0\\.039480507327075774\ \(0\)\
\-\ san\\:\\ 0\\.035922810727040004\ \(0\)\
\-\ cycles\\:\\ 0\\.035496902841099076\ \(0\)\
\-\ april\\:\\ 0\\.035100392085426944\ \(0\)\
\-\ distributed\\:\\ 0\\.034729481044406416\ \(0\)\
\-\ lymphoid\\:\\ 0\\.034729481044406416\ \(0\)\
\-\ topical\\:\\ 0\\.03344704684145119\ \(0\)\
\-\ beam\\:\\ 0\\.03316664359909813\ \(0\)\
\-\ lower\\:\\ 0\\.0331355529200666\ \(0\)\
\-\ june\\:\\ 0\\.03216461263849596\ \(0\)\
\-\ wrists\\:\\ 0\\.031939206241063306\ \(0\)\
\-\ 1998\\:\\ 0\\.03131162410333347\ \(0\)\
\-\ tx\\:\\ 0\\.030397459191668603\ \(0\)\
\-\ clinical\\:\\ 0\\.0302219517248966\ \(0\)\
\-\ corticosteroids\\:\\ 0\\.02991149719150732\ \(0\)\
\-\ infiltrate\\:\\ 0\\.029183039113121433\ \(0\)\
\-\ erythematous\\:\\ 0\\.02853661392101402\ \(0\)\
\-\ cutaneous\\:\\ 0\\.02853661392101402\ \(0\)\
\-\ lymphoma\\:\\ 0\\.028071248671143512\ \(0\)\
\-\ scalp\\:\\ 0\\.027738703318403585\ \(0\)\
\-\ seminar\\:\\ 0\\.027328019617356775\ \(0\)\
\-\ uniformed\\:\\ 0\\.0270381871252482\ \(0\)\
\-\ sites\\:\\ 0\\.026762272072453023\ \(0\)\
\-\ services\\:\\ 0\\.026498998876870877\ \(0\)\
\-\ dermatology\\:\\ 0\\.026498998876870877\ \(0\)\
\-\ hands\\:\\ 0\\.02540844407640264\ \(0\)\
\-\ feet\\:\\ 0\\.025131420502736677\ \(0\)\
\-\ scheduled\\:\\ 0\\.024739419065802577\ \(0\)\
\-\ annual\\:\\ 0\\.024614476613869205\ \(0\)\
\-\ residual\\:\\ 0\\.024372456583121354\ \(0\)\
\-\ face\\:\\ 0\\.024083595463690956\ \(0\)\
\-\ bilateral\\:\\ 0\\.023836985394418895\ \(0\)\
\-\ felt\\:\\ 0\\.02310188435844688\ \(0\)\
\-\ represent\\:\\ 0\\.02156852523528466\ \(0\)\
\-\ atypical\\:\\ 0\\.02128465882534457\ \(0\)\
\-\ total\\:\\ 0\\.02114781601675998\ \(0\)\
\-\ previously\\:\\ 0\\.02063087212789251\ \(0\)\
\-\ involved\\:\\ 0\\.020600056362712133\ \(0\)\
\-\ 9\\:\\ 0\\.02030065916797994\ \(0\)\
\-\ presenting\\:\\ 0\\.020016089831615683\ \(0\)\
\-\ skin\\:\\ 0\\.018862809972637805\ \(0\)\
\-\ active\\:\\ 0\\.018750338155430347\ \(0\)\
\-\ diagnosed\\:\\ 0\\.01805859285514371\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.017603136696211868\ \(0\)\
\-\ biopsy\\:\\ 0\\.017423524377222763\ \(0\)\
\-\ was\\:\\ 0\\.01703926762437391\ \(0\)\
\-\ now\\:\\ 0\\.016788020630469237\ \(0\)\
\-\ three\\:\\ 0\\.01655531165716615\ \(0\)\
\-\ revealed\\:\\ 0\\.01576134419463272\ \(0\)\
\-\ follow\\:\\ 0\\.015604594666358816\ \(0\)\
\-\ \\,\\:\\ 0\\.015558049742372838\ \(0\)\
\-\ some\\:\\ 0\\.01491338076934919\ \(0\)\
\-\ 6\\:\\ 0\\.014667357249280887\ \(0\)\
\-\ syndrome\\:\\ 0\\.014045440096176101\ \(0\)\
\-\ weeks\\:\\ 0\\.01393837791322499\ \(0\)\
\-\ all\\:\\ 0\\.013890364881789028\ \(0\)\
\-\ performed\\:\\ 0\\.013692978915099534\ \(0\)\
\-\ months\\:\\ 0\\.013413455716609582\ \(0\)\
\-\ up\\:\\ 0\\.01320601810950703\ \(0\)\
\-\ lesions\\:\\ 0\\.013146899461746825\ \(0\)\
\-\ therapy\\:\\ 0\\.013130119518624212\ \(0\)\
\-\ over\\:\\ 0\\.012503693046781394\ \(0\)\
\-\ on\\:\\ 0\\.012480879523541863\ \(0\)\
\-\ \\(\\:\\ 0\\.012454512521445872\ \(0\)\
\-\ \\)\\:\\ 0\\.012302374001953536\ \(0\)\
\-\ 1\\:\\ 0\\.011685783723906362\ \(0\)\
\-\ 3\\:\\ 0\\.011499859348888159\ \(0\)\
\-\ case\\:\\ 0\\.010744278349811901\ \(0\)\
\-\ had\\:\\ 0\\.010596838041613266\ \(0\)\
\-\ multiple\\:\\ 0\\.01034371266367396\ \(0\)\
\-\ after\\:\\ 0\\.010160926451777026\ \(0\)\
\-\ treatment\\:\\ 0\\.009940327354028087\ \(0\)\
\-\ which\\:\\ 0\\.009167497627830739\ \(0\)\
\-\ for\\:\\ 0\\.008380553432674886\ \(0\)\
\-\ an\\:\\ 0\\.006791177380946723\ \(0\)\
\-\ at\\:\\ 0\\.006653811223170304\ \(0\)\
\-\ and\\:\\ 0\\.005172672578512024\ \(0\)\
\-\ patient\\:\\ 0\\.004922942131703379\ \(0\)\
\-\ to\\:\\ 0\\.004908828832678003\ \(0\)\
\-\ in\\:\\ 0\\.004843646323451206\ \(0\)\
\-\ with\\:\\ 0\\.004034626761720336\ \(0\)\
\-\ of\\:\\ 0\\.002008686220654973\ \(0\)\
\-\ \\.\\:\\ 0\\.0018361829015868763\ \(0\)\
\-\ the\\:\\ 0\\.0015890722379727103\ \(0\)\
